DAFTAR PUSTAKA

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics 2013. Update a report from the American Heart Association. *American Cardiology Intervention J*. 2013; 4:6–11.
2. Ibanez B, James S, Agewall S, Antunes MJ, Ducci CB, Bueno H, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *European Heart J*. 2017; 39:1–66.
3. O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. AHA guideline for the management of ST-elevation myocardial infarction. 2013; 363-425.
4. RISKESDAS. Riset Kesehatan Dasar. Badan Penelitian dan Pengembangan Kesehatan Departemen Kesehatan Republik Indonesia. Jakarta: Kementrian Kesehatan RI. 2018.
5. Dharma S. Infark miokard akut disertai elevasi segmen-ST: Patologi, patofisiologi dan gambaran klinis. In: Buku Ajar Kardiovaskular Jilid 2. 2017. p.153-161.
6. Francone M, Bucciarelli-Ducci C, Carbone I, Canali E, Scardala R, Calabrese FA, et al. Impact of primary coronary angioplasty delay on myocardial salvage, infarct size, and microvascular damage in patients with ST-segment elevation myocardial infarction: insight from cardiovascular magnetic resonance. *American Cardiology Intervention J*. 2009; 54:2145-2153.
7. Tarantini G, Cacciavillani L, Corbetti F, Ramondo A, Marra MP, Bacchiega E, et al. Duration of ischemia is a major determinant of transmurality and severe microvascular obstruction after primary angioplasty: a study performed with contrast-enhanced magnetic resonance. *American Cardiology Intervention J*. 2005; 46:1229-1235.
8. Hannan EL, Zhong Y, Jacobs AK, Holmes DR, Walford G, Venditti FJ, et al. Effect of onset-to-door time and door-to-balloon time on mortality in patients undergoing percutaneous coronary interventions for ST-segment elevation myocardial infarction. *American Cardiology Intervention J*. 2010; 106:143-147.
9. Brodie BR, Hansen C, Stuckey TD, Richter S, Versteeg DS, Gupta N, et al. Door-to-balloon time with primary percutaneous coronary intervention for acute myocardial infarction impacts late cardiac mortality in high-risk patients and patients presenting

early after the onset of symptoms. *American Cardiology Intervention J*. 2006; 47:289-295.

10. Denktas AE, Anderson HV, Mccarthy J, Smalling RW. Total ischemic time: the correct focus of attention for optimal ST-segment elevation myocardial infarction care. *American Cardiology Intervention J*. 2011; 4:599-604.
11. Guerchicoff A, Brener SJ, Maehara A, Witzenbichler B, Fahy M, Xu K, et al. Impact of delay to reperfusion on reperfusion success, infarct size, and clinical outcomes in patients with STEMI. *American Cardiology Interventions J*. 2014; 7:733-740.
12. Khowaja S, Ahmed S, Khan NU, Saghir T, Nadeem S, Qamar N, et al. Time to think beyond door to balloon time: significance of total ischemic time in patients with ST elevation myocardial infarction. *American Cardiology J*. 2019; 73:227.
13. Park J, Choi KH, Lee JM, Kim HK, Hwang D. Prognostic implications of door-to-balloon time and onset-to-door time on mortality in patients with st-segment–elevation myocardial infarction treated with primary percutaneous coronary intervention. *American Cardiology J*. 2019; 8:1-12.
14. Khalid U, Jneid H, Denktas AE. The relationship between total ischemic time and mortality in patients with STEMI every second counts. *Cardiovascular Diagnosis Therapy J*. 2017; 119-124.
15. Shiomi H, Nakagawa Y, Morimoto T, Furukawa Y, Nakano A. Association of onset to balloon and door to balloon time with long term clinical outcome in patients with ST elevation acute myocardial infarction having primary percutaneous coronary intervention: observational study. *British Med J*. 2012; 344:3257.
16. Song F, Yu M, Yang J. Symptom-onset-to-balloon time, ST-segment resolution and in-hospital mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention in China: from china acute myocardial infarction registry. American Cardiology J. 2016; 1-6.
17. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. Pedoman tatalaksana sindroma koroner akut. Edisi Keempat. Jakarta: 2018.
18. Dharma S, Andriantoro H, Dakota I, Purnawan I, Pratama V, Isnanijah H, et al. Organisation of reperfusion therapy for STEMI in a developing country. *Open Heart J*. 2015; 2:240.

19. Kaptoge S, Pennells L, De Bacquer D, Cooney MT, Kavousi M, Stevens G, et al. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. *The Lancet Global Health J*. 2019;7(10):1332-1345.
20. Tobing D. Buku Ajar Kardiovaskular Jilid 2 Bab 43: Tatalaksana infark miokard elevasi segmen ST. Departemen Kardiologi dan Kedokteran Vaskular FKUI. Jakarta: 2017.
21. Antman EM. ST-segment elevation myocardial infarction: pathology, pathophysiology, and clinical features. In: Braunwald's Heart Disease : A Textbook of Cardiovascular Medicine. 2012. p. 1087–1110.
22. Thygesen K, Alpert JS, Jaffe AF, Chaitman BR, Bax JJ, Morrow D, et al. Fourth universal definition of myocardial infarction. *European Heart J*. 2018; 1–33.
23. Zheng W, Yu CM, Liu J, Xie WX, Wang M, Zhang YJ, et al. Patients with ST-segment elevation of myocardial infarction miss out on early reperfusion: when to undergo delayed revascularization. *Geriatric Cardiology J*. 2017; 14:524–531.
24. Tsai IT, Wang CP, Lu YC, Hung WC, Wu CC, Lu LF, et al. The burden of major adverse cardiac events in patients with coronary artery disease. *BMC Cardiovascular Disorders J*. 2017; 17: 1.
25. Prasad A, Stone GW, Holmes DR, Gersh B. Reperfusion injury, microvascular dysfunction, and cardioprotection the "dark side" of reperfusion. *American Cardiology J*. 2009; 120:2105-2112.
26. Ferrari R, Balla C, Malagu M, Guardigli G, Morciano G, Bertini M, et al. Reperfusion damage. *Circulation J*. 2016; 16:1124-1135.
27. Solhpour A, Chang KW, Arain SA, Balan P, Loghin C, et al. Ischemic time is a better predictor than door-to-balloon time for mortality and infarct size in ST-elevation myocardial infarction. *Catheter Cardiovascular Intervention J*. 2016; 87:1194-1200.
28. Hosseiny AD, Moloi S, Chandrasekhar J, Farsh A. Mortality pattern and cause of death in a long-term follow-up of patients with STEMI treated with primary PCI. *Open Heart J*. 2016; 3:1-7.
29. Dharma S, Andriantoro H, Dakota I, Purnawan I, Pratama V, Isnanijah H, et al. Organisation of reperfusion therapy for STEMI in a developing country. *Open Heart J*. 2015; 2:1-7.

30. Baek YS, Park SD, Kim SH, Lee ML, Shin SH, Vernon AH, et al. Clinical and angiographic predictors of microvascular dysfunction in ST-segment elevation myocardial infarction. *Yonsei Med J*. 2015; 56:1235-1243.
31. Hahn JY, Song YB, Gwon HC, Choe Yh, Kim JH, Sung J, et al. Relationof the left ventricular infarct transmurality and infarct size after primary percutaneous coronary angioplasty to time from symptom onset to balloon inflation. *American Cardiology J*. 2008; 102: 1163-1169.
32. Heitzler VN, Milicic D, Babic Z, Boersma E, Zijlstra F, Yu H, et al. Evaluation of importance of door to balloon and total ischemic time in AMI with ST-elevation treated with PPCI. *Acta Clinical Croatian J*. 2012; 51:387-395.
33. Sardar MR, Abbott JD. Myocardial salvage and mortality in dysfunction in ST-segment elevation myocardial infarction a race against ischemic time, catheterization and cardiovascular interventions. *Catheterization and Cardiovascular Interventions J*. 2016; 87:1201–1202.
34. Eitel I, Desch S, Fuernau G, Hildebrand L, Gutberlet M, Schuler G, et al. Prognostic significance and determinants of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. *American Cardiology J*. 2010; 55: 2470 –2479.
35. Polanska-Skrzypczyk M, Karcz M, Bekta P, Kepka C, Sielatycki P, Ruzyllo W, et al. Total ischemic time and 9-year outomes in dysfunction in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. *International of Cardiology J*. 2015; 184–189.
36. Irmawartini, Nurhaedah. Metodologi penelitian. Kemeterian Kesehatan Republik Indonesia; 2017.
37. Hoes AW, Ireland MC, Corra U, Ireland IG, Stephen M, Sattar N, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice the sixth joint task force of the european society of cardiology. *G Italian Cardiology J*. 2016; 37:2315–2381.
38. Soelistijo SA, Novida H, Rudijanto A, Soewondo P, Suastika K, Manaf A, et al. Konsensus pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia. Jakarta: PB. PERKENI; 2015.

39. Poppe K. What is normal left ventricular ejection fraction? A global individual person data meta-analysis of the distribution across ethnicity, gender and age. *European Heart J*. 2013; 34:348.
40. Ahmed F, Rahman A, Rahman MA, Chowdhury TA, Chowdhury MSH, Uddin SN, et al. Predictors of short-term outcomes of primary percutaneous coronary intervention. *Bangladesh Heart J*. 2018; 33(2):112-120.
41. Hamilton DS, Tankazyan DOH, Khachtryan T, Desai A, Evans BSJ, Suh E, et al. Factors affecting time to presentation in ST-elevation myocardial infarction (FAT STEMI). *Clin Exp Cardiolog J*. 2017; 8(2):1-4.
42. Hu R, Liu J, Zhou Y, Hu B. Association of smoking with restenosis and major adverse cardiac events after coronary stenting: a meta-analysis. *Pak Med Sci J*. 2015; 31(4):1002-1008.
43. Ye, Lu H, Li L. Reduced left ventricular ejection fraction is a risk factor for in-hospital mortality in patients after percutaneous coronary intervention: a hospital-based survey. *BioMed Research International J*. 2018; 1-8.
44. Cohen M, Boiangiu C, Abidi M. Therapy for ST-segment elevation myocardial infarction patients who present late or are ineligible for reperfusion therapy. *American College of Cardiology J*. 2010; 55(18):1896-1906.
45. Fajar JK, Mahdi BA, Heriansyah T, Rohman MS. Length of stay and major adverse cardiac events, comparison between percutaneous coronary intervention and thrombolytic therapy in patients with ST-elevation myocardial infarction, implication for cost effectiveness. *Archives of Hellenic Medicine J*. 2019; 36(4):494-502.
46. Montone RA, Crea F. Clinical implications and treatment of coronary microvascular obstruction in STEMI. *Cardiac Intervention J*. 2020;14(3):40-45.